Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation

Covalent CDK7 inhibitor THZ1 is a newly discovered anti-tumor drug.THZ1 affects the function of transcription factor TFIIH by inhibiting CDK7, which in turn affects RNA polymerase II, and ultimately affects transcription initiation. Study found that THZ1 could inhibit proliferation and promote apopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xinqi, Kuang, Xielan, Xia, Qing, Huang, Zixin, Fan, Yuting, Ning, Jie, Wen, Jiajie, Zhang, Han, Yan, Jianhua, Zhang, Qingjiong, Shen, Huangxuan, Long, Chongde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134829/
https://www.ncbi.nlm.nih.gov/pubmed/30210638
http://dx.doi.org/10.7150/jca.25395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134829/
https://www.ncbi.nlm.nih.gov/pubmed/30210638
http://dx.doi.org/10.7150/jca.25395

Ejemplares similares